Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States

Shaji K. Kumar, Istvan Majer, Sumeet Panjabi, Rohan Medhekar, Marco Campioni, Meletios A. Dimopoulos

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States'. Together they form a unique fingerprint.

Medicine & Life Sciences